MindMaze Therapeutics Holding S.A. Sponsored ADR

FRC's fair value estimate for MindMaze Therapeutics Holding S.A. Sponsored ADR, and the rating behind it. RLFTY last traded at $0.95; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for MindMaze Therapeutics Holding S.A. Sponsored ADR. Starting points for MindMaze Therapeutics Holding S.A. Sponsored ADR: EPS -$0.99, beta 0.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for MindMaze Therapeutics Holding S.A. Sponsored ADR. MindMaze Therapeutics Holding S.A. Sponsored ADR does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for MindMaze Therapeutics Holding S.A. Sponsored ADR. Trailing twelve-month EPS for MindMaze Therapeutics Holding S.A. Sponsored ADR stands at -$0.99. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for MindMaze Therapeutics Holding S.A. Sponsored ADR. MindMaze Therapeutics Holding S.A. Sponsored ADR has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

MindMaze Therapeutics Holding S.A. Sponsored ADR valued side by side against its closest peers. MindMaze Therapeutics Holding S.A. Sponsored ADR is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold MindMaze Therapeutics Holding S.A. Sponsored ADR, and how their positions are changing. At a $12.0M market value, institutional positions materially move MindMaze Therapeutics Holding S.A. Sponsored ADR's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by MindMaze Therapeutics Holding S.A. Sponsored ADR executives and directors. Shares of MindMaze Therapeutics Holding S.A. Sponsored ADR have traded between $0.95 and $4.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming MindMaze Therapeutics Holding S.A. Sponsored ADR. MindMaze Therapeutics Holding S.A. Sponsored ADR is a $12.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming MindMaze Therapeutics Holding S.A. Sponsored ADR. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for MindMaze Therapeutics Holding S.A. Sponsored ADR. Coverage tracks MindMaze Therapeutics Holding S.A. Sponsored ADR within Biotechnology (Healthcare). Press releases and market coverage, newest first.